Futures
Access hundreds of perpetual contracts
TradFi
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Pre-IPOs
Unlock full access to global stock IPOs
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
Promotions
AI
Gate AI
Your all-in-one conversational AI partner
Gate AI Bot
Use Gate AI directly in your social App
GateClaw
Gate Blue Lobster, ready to go
Gate for AI Agent
AI infrastructure, Gate MCP, Skills, and CLI
Gate Skills Hub
10K+ Skills
From office tasks to trading, the all-in-one skill hub makes AI even more useful.
GateRouter
Smartly choose from 40+ AI models, with 0% extra fees
Pfizer and Arvinas' new breast cancer drug approved by the U.S. FDA
On May 1st local time, Arvinas and its partner Pfizer jointly announced that the U.S. Food and Drug Administration (FDA) has approved VEPPANU (vepdegestrant) for the treatment of adult patients with advanced or metastatic breast cancer who have been diagnosed with estrogen receptor-positive (ER+) / human epidermal growth factor receptor 2-negative (HER2-), ESR1 mutation, and whose disease has progressed after at least one endocrine therapy. This is also the FDA’s first approval of a protein degradation targeted chimeric molecule (PROTAC), a type of heterobifunctional protein degrader therapy. (Jiemian News)